Nabila I. Patel, DO – Clinical Research Experience
Precision Research Center, Inc. · 2510 W Waters Ave, Tampa, FL 33614
Profile
Physician with experience as Principal Investigator and Sub-Investigator in industry-sponsored studies in metabolic, renal, respiratory, CNS, GI and infectious disease. Current ICH-GCP training.
Clinical Studies (2020–2026)
| Year | Study | ClinicalTrials.gov |
|---|---|---|
| 2026 | A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia (Novartis CHDY015A12201) | NCT07610278 |
| 2025 | A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | NCT06948435 |
| 2025 | Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals | NCT06817889 |
| 2025 | Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression | NCT06866236 |
| 2025 | A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants | NCT06942936 |
| 2025 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation (GSK ENDURA, 222714) | NCT06959095 |
| 2025 | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort | NCT07024823 |
| 2025 | A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes | NCT07030868 |
| 2025 | A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Early Depemokimab Initiation as Add-On Treatment in COPD Patients With Type 2 Inflammation (GSK Vigilant, 224295) | NCT07177339 |
| 2025 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (Alnylam ALN-AGT01-008) | NCT07181109 |
| 2025 | A Phase II Randomised, Double-blind, Parallel-group, Multicentre, International Trial to Investigate the Safety and Efficacy of Vicadrostat and Empagliflozin Administered With Simultaneous vs Staggered Initiation in Participants With Chronic Kidney Disease at Risk of Kidney Disease Progression (Boehringer Ingelheim 1378-0023) | NCT06926660 |
| 2024 | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression (Merck MK4482-023) | NCT06667700 |
| 2024 | A Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in Subjects with Major Depressive Disorder | NCT06360419 |
| 2024 | Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes Mellitus | NCT04838392 |
| 2024 | An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study | NCT06534892 |
| 2023 | A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With Standard Risk for Developing Severe Disease | NCT05715528 |
| 2023 | A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT) | NCT06011577 |
| 2023 | A randomized, double-blind, multicenter, phase III study to evaluate the long-term efficacy and safety of obefazimod 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis | NCT05535946 |
| 2023 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | NCT06223880 |
| 2023 | A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4) | NCT05803421 |
| 2022 | Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU) | NCT05528861 |
| 2022 | A multicenter, randomized, double-blind, placebo-controlled 12-week study to evaluate the safety and efficacy of oral difelikefalin in advanced chronic kidney disease subjects with moderate-to-severe pruritus and not on dialysis with an up to 52-week long-term extension | — |
| 2022 | A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis | NCT05507203 |
| 2022 | A Randomized, Double-blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Alzheimer’s Disease Agitation | NCT05557409 |
| 2022 | Randomized, double-blind, placebo-controlled, parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease | NCT05182840 |
| 2022 | An open-label, long-term extension study to evaluate the safety and tolerability of Simufilam 100 mg tablets in participants with mild to moderate Alzheimer’s disease | NCT05575076 |
| 2022 | A 3-year, 3-group, preference, multi-center study to demonstrate the slowing of disease progression when switching from cigarette smoking to the Tobacco Heating System (THS) in mild to moderate Chronic Obstructive Pulmonary Disease (COPD) subjects with a history of chronic bronchitis symptoms | NCT05569005 |
| 2022 | A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients with Treatment-Resistant Depression | NCT05113771 |
| 2022 | A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease | NCT05312879 |
| 2021 | A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE) | NCT04859517 |
| 2021 | A randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacokinetics of intranasal STI-2099 (COVI-DROPS™) in outpatient adults with COVID-19 | NCT04906694 |
| 2021 | Efficacy and safety of GMRx2 (a single pill combination containing telmisartan/amlodipine/indapamide) compared to dual combinations for the treatment of hypertension: An international, multi-center, randomized, double-blind, active-controlled, parallel-group trial | NCT04518293 |
| 2021 | Efficacy and safety of GMRx2 (a single pill combination containing telmisartan/amlodipine/indapamide) compared to placebo for the treatment of hypertension: An international, multi-center, randomized, double-blind, placebo-controlled, parallel-group trial | NCT04518306 |
| 2021 | A Randomized, Double-blind (Patient, Investigator), Placebo-controlled, Dose-escalation Study on Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of BI 1569912 as Adjunctive Therapy in Patients with Major Depressive Disorder After Single Oral Dosing, Phase I | NCT04937829 |
| 2021 | A Phase 1b, Multiple Ascending Dose Trial Examining the Safety and Tolerability of Subcutaneous MANP in Difficult to Control/Resistant Hypertensive Subjects, Phase I | NCT05247528 |
| 2021 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100mg Tablets in Subjects with Mild to Moderate Alzheimer’s Disease | NCT04994483 |
| 2021 | A phase 3, randomized, double-blind, placebo-controlled, parallel-group, 76-week study evaluating the safety and efficacy of two doses of Simufilam in subjects with mild-to-moderate Alzheimer’s disease | NCT05026177 |
| 2021 | Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety and Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years and Older with a History of Urinary Tract Infection in the Past 2 Years | NCT04899336 |
| 2021 | An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects with Dementia of the Alzheimer’s Type | NCT04947553 |
| 2020 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for the Treatment of Confirmed COVID-19 in Outpatient (CAMostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 [CAMELOT]) | NCT04583592 |
| 2020 | A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | NCT04313023 |
| 2020 | A Phase II/III randomized, multi-center, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) in nonhospitalized patients | NCT04545060 |
| 2020 | A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19 | NCT04625972 |
| 2020 | A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type | NCT04408755 |